FDAnews
www.fdanews.com/articles/75139-hana-biosciences-awarded-159-000-nih-grant-for-expanded-preclinical-development-of-talotrexin

HANA BIOSCIENCES AWARDED $159,000 NIH GRANT FOR EXPANDED PRECLINICAL DEVELOPMENT OF TALOTREXIN

August 8, 2005

Hana Biosciences, Inc. (OTCBB: HNAB - News), a South-San Francisco based biopharmaceutical company focused on advancing cancer care, was awarded a $159,000 Small Business Innovation Research (SBIR) grant entitled "Development of PT-523 for the treatment of lung cancer" by the National Institutes of Health (NIH). The award will enable Hana Biosciences to expand preclinical studies of Talotrexin in combination with other therapeutic agents as a potential first-in-class therapeutic approach to treating various forms of cancer.

Yahoo News (http://biz.yahoo.com/bw/050808/85330.html?.v=1)